NUTX
Nutex Health Inc.171.72
-4.06-2.31%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
IDR trends improve; expansion clarified
Q&A shed light on maturing IDR dynamics, with submissions dropping to 50-60% from prior 60-70% yet collections reaching 85% as payers settle more upfront via negotiations. Management detailed reopening the Amble, Texas hospital, viable now due to IDR-driven reimbursements and stronger inpatient capabilities. Confirmed three firm 2026 openings—Jacksonville, West Little Rock, San Antonio—while elaborating on sale-leaseback strategy to recycle capital accretively for further pipeline. True-up emerged mid-Q4, mostly low-acuity ER claims; future ineligibles will accrue promptly. IDR is maturing fast. Tone stayed confident on growth execution.
Key Stats
Market Cap
1.21BP/E (TTM)
8.38Basic EPS (TTM)
20.49Dividend Yield
0%Recent Filings
8-K
2025 revenue up 82.4%
Nutex Health crushed 2025 with revenue surging 82.4% to $875.3M, net income up to $70.8M, and Adjusted EBITDA rocketing 152.6% to $259.6M, fueled by hospital growth and IDR wins. Q4 revenue dipped 41.1% to $151.7M from arbitration true-ups, yet adjusted figures show underlying gains. Board greenlit $25M stock buyback over six months. Cash balance hit $185.6M.
10-K
FY2025 results
Nutex Health crushed FY2025 with hospital revenue exploding 88% y/y to $844M, fueled by IDR arbitration wins under the No Surprises Act that boosted revenue per visit while patient visits climbed 11.8% to 188k—mature facilities up 1.3% y/y, plus two new openings. Q4 accelerated the momentum, contributing to $259M Adjusted EBITDA (up 153% y/y) as margins expanded on higher acuity cases like observation/inpatient stays, though arbitration costs hit $138M annually. Strong cash generation swelled liquidity to $186M, funding $25M buybacks (completed post-year-end) and new facilities; debt covenants intact with $5M revolver room. Plans call for four hospital openings and 1-3 IPAs in 2026. No quarterly breakdowns disclosed. Regulatory flux around No Surprises Act IDR rules risks reimbursement volatility.
8-K
Auditors' consent filed
Nutex Health filed an 8-K on November 24, 2025, disclosing auditors' consent from Marcum LLP as Exhibit 23.1. This consent allows incorporation by reference of their audit report on the company's 2023 consolidated financials into prior registration statements. Filing follows the Form 10-K/A amendment on November 18. Routine housekeeping.
8-K
Q3 revenue up 240%
Nutex Health crushed Q3 with revenue surging 239.9% to $267.8M, driven by hospital division's $260.2M (up 262.8%) from higher acuity claims and IDR wins—submitting 60-70% of visits, winning 85%+. Net income flipped to $55.4M from $8.8M loss; cash hit $166M. Nasdaq compliance regained. Stock comp spiked to $13.2M.
10-Q
Q3 FY2025 results
Nutex Health crushed Q3 with hospital revenue exploding 240% y/y to $260M on higher visits and IDR wins, driving operating income to $130M from $10M while gross margins soared. Diluted EPS hit $7.76, backed by 6.7M shares. Cash swelled to $166M on $178M operating cash flow (FCF not disclosed in the 10-Q), total debt steady at $49M with $5.9M revolver availability and no covenants. May and September asset acquisitions added real estate and a $7M Certificate of Need, no goodwill. Stock-based comp spiked on hospital earnouts. Ongoing securities and derivative suits pose litigation risk.
IPO
Website
Employees
Sector
Industry
ACHC
Acadia Healthcare Company, Inc.
14.43+0.21
ARDT
Ardent Health, Inc.
8.93+0.03
CYH
Community Health Systems, Inc.
3.25+0.03
EHC
Encompass Health Corporation
108.01+0.42
HCA
HCA Healthcare, Inc.
469.79-7.19
MD
Pediatrix Medical Group, Inc.
22.32-0.37
NHC
National HealthCare Corporation
138.93-0.94
SRXH
SRX Health Solutions, Inc.
0.38+0.07
THC
Tenet Healthcare Corporation
196.88-0.44
UHS
Universal Health Services, Inc.
222.64-1.23